Pharmafile Logo

Communiqué Awards 2016: Excellence in Communication of Survey or Market Research Data

July 13, 2016 | Communiqué Awards, Lucid 

The winning programme – Treating beyond symptoms in IBD: The Steroid Assessment Tool.

Our approach to medical education is really helping to improve patient outcomes and change lives.

Inflammatory bowel disease (IBD) affects more than 250,000 patients in the UK. Treatment strategies have progressed to treating beyond the symptoms of IBD, aiming to reduce mucosal inflammation, sustain remission and prevent bowel damage. 

Steroids have a place in the treatment pathway but do not sustain remission and are associated with significant side effects.The European Crohn’s and Colitis Organisation (ECCO) defines appropriate steroid use and recommends an exit strategy for steroid-dependent patients. However, gastroenterologists are not aware that inappropriate steroid use occurs in their own clinical practice.

Using a simple digital tool, UK experts audited their own practice and were surprised to see high steroid use among their patients. The expert group became advocates for change, motivated to share their data, targeting more than 300 UK HCPs with high steroid use, which comprises approximately 22% of UK IBD clinicians. Awareness of inappropriate steroid use, and the changes driven by the self-realisation of the need to optimise steroids, have the potential to impact the care delivered to over 50,000 UK IBD patients.


This content was provided by Lucid Group Communications Limited

Company Details

 Latest Content from  Lucid Group Communications Limited 

The Lucid Group Guide

We work hard at Lucid Group. Transforming lives, it's not a walk in the park. We’re a team. In fact, we are many teams. Working together to discover, define, design,...

Our #LucidLife

We asked our people: Why do you do what you do? - What makes you get out of bed in the morning? The responses had a common theme - it's...

Lucid Group opens our new space in Marlow

This week marks an important step for everyone here at Lucid Group, as we re-open our premises in the UK and US and evolve to a hybrid way of working....

A personal perspective on autism

The whole month of April is Autism Awareness Month. To help mark the end of such an important month we’re sharing a personal perspective to spread kindness and autism awareness:When...

Lucid Group is building its data analytics capability

Lucid Group is building a new data analytics capability into its teams with the appointment of Darren Selmes as its new analyst. This appointment signals the start of a stronger...

Lucid Group promotes Clare Reynolds to Director of Business Development and Commercial Integration

As Lucid continues to evolve, its people have remained at the heart of its success. Clare Reynolds has played a key part in Lucid’s journey for nearly 12 years, during...

A magic milestone: Sally’s 10-year #LucidLife workiversary

Our people define our culture and there is no better example of what we are striving to achieve than what Sally Ratcliffe, Scientific Director, Lucid Group, has demonstrated over the...

Virtually, the same: Is it time to rethink congress strategy?

In this month’s PME, Jonathan Andrew, Technology Director at Lucid Group discusses the digital transformation that swept through the medcomms industry due to the COVID-19 pandemic. In particular, we saw...

Lucid Group Bolster its Senior Leadership Team

Lucid Group are delighted to welcome Jo Troman to the role of Managing Partner for team Origins. Jo has a wealth of industry experience from both client and agency sides....

Lucid Group Support Autism Awareness Day

Annually, 2 April is Autism Awareness Day. Being autistic does not mean you have an illness or disease; it means your brain works in a different way from other people....